Mouse xenograft models vs GEM models for human cancer therapeutics

DMM Disease Models and Mechanisms

Volumn 1, Issue 2-3, 2008, Pages 78-82

  Richmond, Ann ^a   Yingjun, Su ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; DOXORUBICIN; MELPHALAN; PACLITAXEL; TRASTUZUMAB;

ANEUPLOIDY; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER MODEL; CANCER STAGING; CANCER THERAPY; CELL TYPE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; EDITORIAL; EMBRYO DEVELOPMENT; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUDE MOUSE; PATHOLOGICAL ANATOMY; POSTNATAL DEVELOPMENT; PRECANCER; PRIORITY JOURNAL; REPRODUCIBILITY; SCID MOUSE; TRANSGENE; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; NEOPLASM; TRANSGENIC ANIMAL; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 64249106832     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.000976     Document Type: Editorial

References (18)

1. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. and Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831. (Pubitemid 28311914)
2. Bernard, D., Peakman, M. and Hayday, A. C. (2008). Establishing humanized mice using stem cells: maximizing the potential. Clin. Exp. Immunol. 152, 406-414. (Pubitemid 351661510)
3. Davis, D. W., Inoue, K., Dinney, C. P., Hicklin, D. J., Abbruzzese, J. L. and McConkey, D. J. (2004). Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. 64, 4601-4610. (Pubitemid 38856934)
4. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E. et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342. (Pubitemid 38702844)
5. Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M. et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431. (Pubitemid 32522115)
6. Kelland, L. R. (2004). Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827-836
7. Kerbel, R. S. (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139.
8. Killion, J. J., Radinsky, R. and Fidler, I. J. (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17, 279-284. (Pubitemid 29210167)
9. LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C. S., Adams, J. et al. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000. (Pubitemid 34984425)
10. Mateos, M. V., Hernandez, J. M., Hernandez, M. T., Gutierrez, N. C., Palomera, L., Fuertes, M., Díaz-Mediavilla J., Lahuerta J. J., de la Rubia, J., Terol, M. J. et al. (2006). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108, 2165-2172. (Pubitemid 44497496)
11. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M. et al. (2003). The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380. (Pubitemid 36302084)
12. Moreau, P., Hulin, C. and Facon, T. (2008). Frontline treatment of multiple myeloma in elderly patients. Blood Rev. 11 Jun [Epub ahead of print].
13. Morton, C. L. and Houghton, P. J. (2007). Establishment of human tumor xenografts in immunodeficient mice. Nat. Protoc. 2, 247-250. (Pubitemid 47040037)
14. Oyajobi, B. O. and Mundy, G. R. (2003). Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer 97, 813-817.
15. Scholz, C. C. and Berger, D. P., Winterhalter, B. R., Henss, H. and Fiebig, H. H. (1990). Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur. J. Cancer 26, 901-905.
16. Sporn, J. R. and Bilgrami, S. A. (1999). Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant. Ann. Oncol. 10, 1259-1260.
17. Talmadge, J. E., Singh, R. K., Fidler, I. J. and Raz, A. (2007). Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170, 793-804.
18. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X. and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434. (Pubitemid 36910021)